Mrinalini Dey
@DrMiniDey
Followers
1K
Following
10K
Media
507
Statuses
2K
Clinical Research Fellow @KCLImmunoMicro•Rheumatology Registrar•@EMEUNET rep to EULAR-PARE•Editorial Board @RheumJnl•#Comorbidities #SocialDeterminantsOfHealth
London, England
Joined May 2019
Delighted to share our paper on #multimorbidity in #RA emphasising a need for:.-Operationalised definition of MM.-Clearer distinction between MM & #comorbidity in literature.-Greater understanding of MM to encourage holistic care.@RheumJnl @ElenaNikiUK.
7
13
70
RT @NEJM: Patients with giant-cell arteritis need better treatments. This video, in partnership with @DGlaucomflecken, summarizes new resea….
0
52
0
RT @sil_aps: In Munich 🇩🇪 today with the @eular_org #PARE committee, working already on topics like the November Conference or 2026 EULAR C….
0
4
0
Catch up on #RheumatoidArthritis highlights from #EULAR2025 with the @RheumNow round-up!. A pleasure to discuss all things RA with RheumNow Royalty, Drs John Cush, @Janetbirdope & Jonathan Kay. Watch here: Listen here:
lnkd.in
This link will take you to a page that’s not on LinkedIn
EULAR 2025 – RA Panel Discussion . Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care.
0
1
5
RT @LupusEurope: 🦋 Thank you to @DrMiniDey from RheumNow for this great interview on #LupusGPT & #EasyLupus!. Don’t miss our Chair, @Jeanet….
0
4
0
🤩So excited about this interview!. 💻#LupusGPT was winning awards at #EULAR2025. 🎙️Delighted to meet with Zoe & @Jeanette_Lupus from @LupusEurope to find out about this exciting development in patient information & use of #AI in #rheumatology. @RheumNow.
2
6
16
Going live in 10 minutes!. Recap of the #RheumatoidArthritis at #EULAR2025, live on @YouTube via @RheumNow . Watch via the link below:.
0
0
0
#EULAR2025: busy but brilliant!. Discussed #HealthLiteracy in 3 abstracts & #syndemics SG. Great to see #HealthInequalities highlighted!. Loved helping organise the #EMEUNET X PARE speed-dating & chairing PARE fatigue session. Lots of great science!. Bring on London #EULAR2026!
2
0
13
A pleasure to once again organise the @EMEUNET X PARE speed dating, this yr expertly curated by @krystelaouad!. There was such a buzz & I was delighted to discuss #SharedDecisionMaking &treatment adherence with our fantastic patients. Thanks to all involved!.#EULAR2025.@RheumNow.
Discussion about Shared decision making and treatment adherence at The EMEUNET meets PARE speed dating.#EULAR2025 #EMEUNET
1
1
15
🕵🏻 Did you do the escape rooms at #EULAR2025?. 🙏🏼⭐️ Huge thanks to @cr_calomarde & @ugara96 who organised and curated this fantastic activity!. 🧩🔎 Much needed downtime, educational & something different between the lectures & talks!. 👏🏼 Congrats & thank you!. @RheumNow.
Our last year trainees (Dr Ugena & Dr Calomarde) have organized the funniest escape room in #EULAR ! .Congrats for the amazing game and for the great success! .We're really proud of you! 🥰#EMEUNET .@emeunet .#EULAR2025
1
2
12
Thank you #EULAR #PARE for the invitation to chair this important session. I learnt a lot and we really could have kept the discussions going for a long time!. #EULAR2025.
@LupusEurope @PFMDwithPatient @SimonRStones @Jeanette_Lupus @fibrofella #EULAR2025 #PARE #Highlights:.The Sleep Struggle: Navigating Fatigue in RMDs, chaired by @DrMiniDey and Marcos Séneca
0
1
7
APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA.✅ ACR20: 67–68% vs 47% (PBO).✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35).No new safety signals identified. @RheumNow #EULAR2025 #LB0010
0
3
4
In a 1st-in-human trial, allogeneic CD19 CAR-NK cell therapy was safe and effective in severe refractory #SLE. No neurotoxicity or ≥G2 CRS. At 12m, 67% achieved DORIS remission, 75% LLDAS. An alternative to autologous #CART?.@RheumNow #EULAR2025 #LB0009.
0
0
0
🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL. 💊Potential new oral ULT option. @RheumNow #EULAR2025 #LB0008
1
2
4
💉Early results from a dose-escalation trial of novel CD19xCD3xCD28 trispecific antibody (CC312) in refractory #SLE show no ICANS or ≥G2 CRS, rapid B cell depletion & 100% SRI-4 response (n=5). @RheumNow #EULAR2025 #LB0007 #CART.
0
2
3
In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS. Remission matters for subsequent Tx reduction. @RheumNow #EULAR2025 #LB0006.
0
1
1
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens. ⭐️🌱STAR/CRESS response rates also favoured active treatment. Safe, accessible, affordable option for active disease. @RheumNow #EULAR2025 #LB0005.
0
1
0
🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability. @RheumNow #EULAR2025 #LB0004.
0
1
4
🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID). Acceptable safety profile & tolerability. @RheumNow #EULAR2025 #LB0003
0
4
6